title: Diffuse alveolar hemorrhage following gemtuzumab ozogamicin.
authors.forename: T S
authors.initials: TS
authors.lastname: Lin
authors.forename: S L
authors.initials: SL
authors.lastname: Penza
authors.forename: B R
authors.initials: BR
authors.lastname: Avalos
authors.forename: M R
authors.initials: MR
authors.lastname: Lucarelli
authors.forename: S S
authors.initials: SS
authors.lastname: Farag
authors.forename: J C
authors.initials: JC
authors.lastname: Byrd
authors.forename: E A
authors.initials: EA
authors.lastname: Copelan
mesh_terms: D000617:Aminoglycosides / Q000009:adverse effects*; D000911:Antibodies, Monoclonal / Q000009:adverse effects* / Q000737:chemistry; D061067:Antibodies, Monoclonal, Humanized; D000079982:Gemtuzumab; D006470:Hemorrhage / Q000139:chemically induced*; D006801:Humans; D000922:Immunotoxins / Q000009:adverse effects*; D015470:Leukemia, Myeloid, Acute / Q000188:drug therapy; D008297:Male; D008875:Middle Aged; D011650:Pulmonary Alveoli / Q000187:drug effects* / Q000473:pathology; D012074:Remission Induction; D033581:Stem Cell Transplantation; D013256:Steroids / Q000627:therapeutic use; D013997:Time Factors
chemical_list: D000617:Aminoglycosides; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000922:Immunotoxins; D013256:Steroids; D000079982:Gemtuzumab